BioCentury | Aug 22, 2016
Clinical News

Axalimogene filolisbac: Phase II data

...IV vaccinations with 1x10 9 colony forming units (CFUs) of axalimogene filolisbac followed by ablative transoral...
BioCentury | Jan 27, 2014
Clinical News

ADXS-HPV: Phase I/II started

...open-label, U.S. Phase I/II trial to compare 2 vaccinations of IV ADXS-HPV followed by ablative transoral...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

...Transcend Medical Inc. as other examples of the strategy. Satiety is testing the catheter-based TOGA transoral...
BioCentury | Mar 31, 2008
Finance

Ebb & Flow

...new investments will be made from the fund. Phase III pitch Specialty pharma Transcept (formerly TransOral...
BioCentury | Jul 2, 2007
Company News

TransOral drug delivery, neurology news

...The company changed its name to Transcept Pharmaceuticals Inc. TransOral Pharmaceuticals Inc. , Pt. Richmond, Calif. Business: Drug...
BioCentury | Mar 12, 2007
Finance

Ebb & Flow

...2Q08 and a drug delivery platform to enhance the speed of onset for existing drugs, TransOral...
...Venture Partners; Montreux Equity Partners; InterWest Partners; Hamilton BioVentures; Vivo Ventures; and Peninsula Equity Partners. TransOral...
...the NDA submission for Intermezzo , a low-dose sublingual formulation of zolpidem to treat insomnia. TransOral...
BioCentury | Mar 7, 2007
Financial News

TransOral raises $40 million

...and Peninsula Equity Partners also participated. TransOral reformulates marketed CNS drugs using its Bimucoral technology. TransOral's...
BioCentury | Oct 29, 2005
Financial News

TransOral raises $23 million

...Drug delivery company TransOral (Corte Madera, Calif.) raised $23 million in a series C round led...
...Partners; Hamilton BioVentures; Vivo Ventures; and Peninsula Equity Partners. New Leaf Venture's Kathy LaPorte joined TransOral's...
BioCentury | Feb 28, 2005
Company News

Neosil board of directors update

...Neosil Inc. , Emeryville, Calif. Business: Dermatology Appointed: Glenn Oclassen, president and CEO of TransOral Pharmaceuticals WIR...
BioCentury | Jan 19, 2004
Finance

Ebb & Flow

...in its portfolio include pain play NeurogesX , GERD play Enteric , drug deliver play TransOral...
Items per page:
1 - 10 of 17
BioCentury | Aug 22, 2016
Clinical News

Axalimogene filolisbac: Phase II data

...IV vaccinations with 1x10 9 colony forming units (CFUs) of axalimogene filolisbac followed by ablative transoral...
BioCentury | Jan 27, 2014
Clinical News

ADXS-HPV: Phase I/II started

...open-label, U.S. Phase I/II trial to compare 2 vaccinations of IV ADXS-HPV followed by ablative transoral...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

...Transcend Medical Inc. as other examples of the strategy. Satiety is testing the catheter-based TOGA transoral...
BioCentury | Mar 31, 2008
Finance

Ebb & Flow

...new investments will be made from the fund. Phase III pitch Specialty pharma Transcept (formerly TransOral...
BioCentury | Jul 2, 2007
Company News

TransOral drug delivery, neurology news

...The company changed its name to Transcept Pharmaceuticals Inc. TransOral Pharmaceuticals Inc. , Pt. Richmond, Calif. Business: Drug...
BioCentury | Mar 12, 2007
Finance

Ebb & Flow

...2Q08 and a drug delivery platform to enhance the speed of onset for existing drugs, TransOral...
...Venture Partners; Montreux Equity Partners; InterWest Partners; Hamilton BioVentures; Vivo Ventures; and Peninsula Equity Partners. TransOral...
...the NDA submission for Intermezzo , a low-dose sublingual formulation of zolpidem to treat insomnia. TransOral...
BioCentury | Mar 7, 2007
Financial News

TransOral raises $40 million

...and Peninsula Equity Partners also participated. TransOral reformulates marketed CNS drugs using its Bimucoral technology. TransOral's...
BioCentury | Oct 29, 2005
Financial News

TransOral raises $23 million

...Drug delivery company TransOral (Corte Madera, Calif.) raised $23 million in a series C round led...
...Partners; Hamilton BioVentures; Vivo Ventures; and Peninsula Equity Partners. New Leaf Venture's Kathy LaPorte joined TransOral's...
BioCentury | Feb 28, 2005
Company News

Neosil board of directors update

...Neosil Inc. , Emeryville, Calif. Business: Dermatology Appointed: Glenn Oclassen, president and CEO of TransOral Pharmaceuticals WIR...
BioCentury | Jan 19, 2004
Finance

Ebb & Flow

...in its portfolio include pain play NeurogesX , GERD play Enteric , drug deliver play TransOral...
Items per page:
1 - 10 of 17